Immunohistochemical FAP Expression Reflects

FAPI IHC IPMN PDAC fibroblast activation protein α-SMA

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
02 Jan 2024
Historique:
received: 18 07 2023
revised: 17 10 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typically > 5 mm) intraductal epithelial neoplasms of mucin-producing cells, arising in the main pancreatic duct or its branches. According to the current 2-tiered grading scheme, these lesions are categorized as having either low-grade (LG) dysplasia, which has a benign prognosis, or high-grade (HG) dysplasia, which formally represents a carcinoma in situ and thus can transform to pancreatic ductal adenocarcinoma (PDAC). Because both entities require different treatments according to their risk of becoming malignant, a precise pretherapeutic diagnostic differentiation is inevitable for adequate patient management. Recently, our group has demonstrated that

Identifiants

pubmed: 38167622
pii: jnumed.123.266393
doi: 10.2967/jnumed.123.266393
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-58

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Anna-Maria Spektor (AM)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Ewgenija Gutjahr (E)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Matthias Lang (M)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Frederik M Glatting (FM)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Molecular and Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.

Thilo Hackert (T)

Department of General, Visceral, and Thoracic Surgery, University Hospital Hamburg, Hamburg, Germany.

Thomas Pausch (T)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Christine Tjaden (C)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Mathias Schreckenberger (M)

Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; and.

Uwe Haberkorn (U)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.

Manuel Röhrich (M)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; manuel.roehrich@med.uni-heidelberg.de.
Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; and.

Classifications MeSH